Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Biogen Inc (NASDAQ:BIIB)

287.77
Delayed Data
As of Dec 09
 -1.77 / -0.61%
Today’s Change
223.02
Today|||52-Week Range
333.65
-6.06%
Year-to-Date
Is Biogen's Aducanumab a Game-Changing Alzheimer's Drug?
Dec 10 / MotleyFool.com - Paid Partner Content
Stocks on Track for Fresh Records as Health Care Sector Climbs
Dec 09 / TheStreet.com - Paid Partner Content
Week in Review: Dow Scores Five Straight Days of Record Closes
Dec 09 / TheStreet.com - Paid Partner Content
Stock Market News for December 09, 2016
Dec 09 / Zacks.com - Paid Partner Content
Dow, in Another Record Close, Ends With Weekly Gains for Fifth Consecutive Week
Dec 09 / TheStreet.com - Paid Partner Content
Jim Cramer -- Be Careful With Biogen; Apple Is Waking Up
Dec 09 / TheStreet.com - Paid Partner Content
Technical Alert: Biogen Inc. Higher Off Trial Results For Aducanumab
Dec 09 / Benzinga - Paid Partner Content
Attention Shifts to Biogen's Alzheimer's Drug in Wake of Lilly Results
Dec 09 / TheStreet.com - Paid Partner Content
Does New Alzheimer's Data Make Biogen Stock a Buy Now?
Dec 09 / MotleyFool.com - Paid Partner Content
The 3 Best Biotech Stocks for 2017
Dec 08 / MotleyFool.com - Paid Partner Content

Today’s Trading

Previous close289.54
Today’s open305.24
Day’s range281.79 - 306.98
Volume6,257,682
Average volume (3 months)1,635,257
Market cap$62.6B
Dividend yield--
Data as of 4:14pm ET, 12/09/2016

Growth & Valuation

Earnings growth (last year)+24.01%
Earnings growth (this year)+18.73%
Earnings growth (next 5 years)+9.50%
Revenue growth (last year)+8.60%
P/E ratio16.3
Price/Sales7.60
Price/Book6.71

Competitors

 Today’s
change
Today’s
% change
GILDGilead Sciences+0.68+0.94%
AMGNAmgen+2.86+2.03%
ILMNIllumina Inc-0.28-0.23%
TECHBio-Techne Corp-0.54-0.50%
Data as of 4:00pm ET, 12/09/2016

Financials

Next reporting dateFebruary 1, 2017
EPS forecast (this quarter)$4.99
Annual revenue (last year)$9.3B
Annual profit (last year)$3.5B
Net profit margin38.05%

Profile

Sector
Health Technology
Industry
Biotechnology
Chief Executive Officer &
Director
George A. Scangos
Chief Scientific Officer &
Executive VP
Spyridon Artavanis-Tsakonas
Corporate headquarters
Cambridge, Massachusetts

Forecasts


Search for Jobs